| Dokumendiregister | Terviseamet |
| Viit | 8-2/25/9278-2 |
| Registreeritud | 25.11.2025 |
| Sünkroonitud | 26.11.2025 |
| Liik | Sissetulev dokument |
| Funktsioon | 8 Nakkushaiguste seire, ennetuse ja tõrje korraldamine |
| Sari | 8-2 Nakkushaiguste epidemioloogiaalane riigiväline kirjavahetus |
| Toimik | 8-2/2025 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | FWD ECDC |
| Saabumis/saatmisviis | FWD ECDC |
| Vastutaja | Liisi Kink (TA, Peadirektori asetäitja (2) vastutusvaldkond, Rahvatervise labor) |
| Originaal | Ava uues aknas |
|
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
To: National Focal Points for FWD, OCPs Microbiology and Epidemiology for Hepatitis A
CC: National Coordinators
Dear Colleagues,
Thank you to all who have already responded to the below email regarding the initiative to set up voluntary Hepatitis E surveillance at the EU/EEA level.
We are pleased to share that so far 10 countries have expressed interest in collaborating on this effort.
For those who have not yet had the opportunity to respond, we warmly encourage you to do so at your earliest convenience. Your input will help us better understand the overall level of interest and ensure that the proposal reflects the needs and priorities across Member States.
For those who have expressed interest, we will follow-up next year with further details and next steps on this topic.
Thank you once again for your engagement and support in strengthening disease surveillance at the EU/EEA level.
On behalf of the FOVEZ team at ECDC,
Best regards,
Liese Van Gompel
From: FWD
ECDC
Sent: 17 November 2025 17:03
To: [email protected]; Christian.Kornschober <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; Mathieu TOURDJMAN <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; Gaia Scavia <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; Lavinia Rusu <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; Helen Byrne <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; Luise Müller <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]
Cc: [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; Nerija Kupreviciene <[email protected]>;
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]
Subject: Expression of interest – voluntary surveillance Hepatitis E
To: National Focal Points for FWD, OCPs Microbiology and Epidemiology for Hepatitis A
Copy: National Coordinators
Dear Colleagues,
I hope this email finds you well.
Following feedback we have received from several Member States in the past years, ECDC is exploring setting up voluntary data collection for Hepatitis E surveillance at the EU/EEA level.
We are currently working on a proposal outlining surveillance objectives, case definitions, and variables to be collected. This proposal will further build on the Hepatitis E guidance developed in 2019 by the ECDC HEV expert group consisting of country nominated experts and scientists working on HEV relevant fields, and will largely reflect the decisions made during this consultation process (https://www.ecdc.europa.eu/sites/default/files/documents/hepatitis-e-guidance.pdf). The final proposal will be discussed in the coming months with countries interested in participating.
To help us plan, we would be grateful if you could let us know by next week Monday 24 November:
- If you would be interested in reviewing the proposal;
- If you would be interested in submitting data starting next year (timeline to be confirmed);
- Who would be the contact person(s) for your country?
We aim to keep data collection practical and focused, avoiding unnecessary details while ensuring a meaningful first step toward coordinated surveillance.
Thank you very much for your consideration, and we look forward to your response.
For your information, in parallel, the ONWARD (One Health Zoonotic Hepevirus Network) project was launched in September 2025 under the European Cooperation in Science and Technology (COST) framework (Action CA24140 - COST), offering ECDC also an opportunity for collaboration while we are setting up the voluntary surveillance; please note that this initiative is independent and not managed by ECDC.
Looking forward hearing from you,
On behalf of the FOVEZ team at ECDC,
Best regards,
Liese Van Gompel
Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it and inform its sender of the erroneous transmittal.
Classified as ECDC NORMAL
| Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
|---|